Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia’s IMMray PanCan-d test

LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) announced, that the Centers for Medicare & Medicaid Services (CMS) published a preliminary payment determination implying a price of $897 for the IMMray PanCan-d test. CMS is a federal agency within the United States Department of Health and Human Services that provides health coverage to more than 100 million people in the U.S. CMS sets the basis for payment for lab tests through the clinical lab free schedule (CLFS).   CMS agreed with the recommendation made by the Clinical Diagnostic Laboratory Tests (CDLT) Advisory Panel to

BioStock Investor Meeting: Interview with Brain+

CEO Kim Baden-Kristensen presented Danish Brain+ at the BioStock Investor Meeting and afterwards BioStock had a chat with him. Among other things, Baden-Kristensen talked more about how the company's digital tools will help people affected by dementia and Alzheimer's and answered the question of whether we are facing a digital revolution in healthcare.See the interview with CEO Kim Baden-Kristensen at biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-brain Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.

Repurchase of NCC Series B shares in week 38, 2022

During the period September 19 – September 23, 2022, NCC (LEI-code 213800WRGLW3CY4MHW53) repurchased a total of 363 543 own Series B shares (ISIN: SE0000117970) under the framework of the repurchase program that the Board have decided.The repurchases are part of the repurchase program of a maximum of 10 percent of Series B shares for a total of not more than SEK 1.5 bn that NCC announced on April 27, 2022. The repurchase program extends from May 11, 2022 until the 2023 Annual General Meeting and is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and

Third Implantation in Sheep Scheduled to Take Place in October

Press Release 26 September, 2022 During the first half of 2022, Realheart performed successful implantations of its total artificial heart in sheep. These implantations are part of a series of implants to test the clinical version of Realheart® TAH. The next implant has been scheduled to take place in October.Preparations for this third implant of the clinical Realheart® TAH version are underway and the implantation will be carried out in an animal laboratory in Belgium by three experienced heart surgeons who have also performed the first two implantations: Dr Dilek Gürsoy, Dr Joeri van

Veg of Lund signs letter of intent for production and distribution of DUG in Southeast Asia

Veg of Lund has signed a Letter of Intent (“LOI”) with DenEast Vietnam Co., Ltd. The companies will cooperate with the common goal of launching, producing and distributing Veg of Lund products under the DUG[®] brand in several countries in Southeast Asia, starting in Vietnam, Thailand and Singapore in early 2023.“The letter of intent is a step in our strategy to license the production of our proprietary foods to established players with extensive experience in premium consumer products. We look forward to working with partners who have a strong position in countries with large populations,

Karo Intressenter AB initiates compulsory redemption

On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) to acquire the shares in Karo Pharma not already held by Karo Intressenter at a price of SEK 60 per share (the “Offer”). On 19 September 2022, Karo Intressenter announced the outcome of the Offer, that they completed the Offer and that Karo Intressenter thereby, at the time of the publication of the announcement, controlled in total approximately 93.7 percent of the total number of shares and votes in Karo Pharma. At

Update on NCC’s earnings

NCC’s operating profit for the third quarter will be negatively impacted by the economic situation, driven primarily by the asphalt operations in the Industry business area. Unrelated to this, a small number of residential projects in Sweden will also be subject to impairment as a result of inadequate project management.“The majority of our projects and businesses are performing well despite strong inflation and economic turbulence. However, the asphalt operations have faced major challenges since we have been unable to fully offset increased costs during the third quarter despite drastic

BioStock Investor Meeting: Interview with Cereno Scientific

Biotech Cereno Scientific develops new treatments for cardiovascular disease, the most common cause of death worldwide. The company's lead candidate CS1 targets the rare disease pulmonary arterial hypertension. CEO Sten R. Sörensen told BioStock more about Cereno Scientific's lead candidate and work during BioStock Investor Meeting.See the full interview with Cereno Scientific's CEO Sten R. Sörensen biostock.se: https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-cereno-scientific 

XNK Therapeutics to use generic name evencaleucel for lead candidate

XNK Therapeutics AB (“XNK”) today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International Nonproprietary Name (INN) for XNK’s leading drug candidate.“We are excited that the WHO now recognizes our leading drug candidate targeting multiple myeloma by recommending the generic name evencaleucel,” said Johan Liwing, CEO of XNK Therapeutics. “XNK recently announced that the first patient with multiple myeloma was treated in a Phase II clinical study

Castellum is among the first to receive NollCO\2\ certification

The Korsningen block project has now been completed, and Castellum is one of the first companies in the Nordics to receive a NollCO2 (ZeroCO2) certification.The Swedish Police Authority, the tenant in the project, has recently moved into the Korsningen office building in central Örebro. The main body of the house – seven storeys tall, built entirely of wood, and encompassing 6,900 square metres of lettable office space – radiates sustainability and innovation. The solar panels on the roof of the property not only supply the building with energy but also generate a surplus of renewable

Nomination committee appointed ahead of 2023 Annual General Meeting of Cloetta AB (publ)

In accordance with the decision of the Annual General Meeting, Cloetta’s nomination committee shall consist of at least four and at most six members. Cloetta hereby announces that the nomination committee now has been appointed ahead of the Annual General Meeting in April 2023.The nomination committee consists of the following members:Lars Schedin, Chairman, appointed by AB Malfors PromotorJohan Törnqvist, appointed by Ulla HåkansonVictoria Lidén, appointed by Storebrand Fonder ABMikael Norman, appointed by the Board of Cloetta AB Cloetta’s 2023 Annual General Meeting will be

Trading in Metacon AB (publ) shares begin today on the Nasdaq First North Growth Market

Metacon AB (publ) ("Metacon" or the "Company") announces that trading in the Company's shares will begin today, 26 September 2022, on the Nasdaq First North Growth Market.The shares are traded on Nasdaq First North Growth Market with unchanged ticker META and ISIN code SE0003086214. There is no offer or issuance of new shares in connection with the Company's shares being admitted to trading on the Nasdaq First North Growth Market. The shareholders of Metacon will not be required to take any action in connection with the list change. "This is a milestone for Metacon and at the same time a

Tele2 signs new agreement with Stena Fastigheter

Tele2 (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) announces it has signed a new agreement with Stena Fastigheter following a procurement process. Tele2 will deliver communication solutions to over 26,000 apartments and 2,000 commercial tenants in Sweden.The agreement Tele2 has signed with Stena Fastigheter is a combination deal that includes Tele2 consumer and business services as well as the communications operator iTUX and Tele2 IoT. The agreement runs until 2029.   - We look forward to being able to develop and offer more services to our tenants together with Tele2. Through

Fortum draws on the liquidity facility provided by the Finnish State – an Extraordinary General Meeting convened to resolve on a directed share issue without payment to Solidium

FORTUM CORPORATION STOCK EXCHANGE RELEASE 26 SEPTEMBER 2022 AT 9:00 EEST Release category: Other information disclosed according to the rules of the Exchange On 6 September 2022, Fortum announced that it had agreed with the Finnish State, Fortum’s majority owner, on a EUR 2.35 billion bridge financing arrangement to ensure access to sufficient liquidity resources for potential collateral requirements on the Nordic commodities exchange Nasdaq in case of rising power prices. According to the terms of the arrangement, the first minimum tranche of EUR 350 million must be drawn latest on

Notice to the Extraordinary General Meeting of Shareholders of Fortum Corporation

FORTUM CORPORATION STOCK EXCHANGE RELEASE 26 SEPTEMBER 2022 AT 9:00 EEST Release category: Notice to convene general meeting The shareholders of Fortum Corporation (“Fortum” or the “Company”) are invited to the Extraordinary General Meeting (the “General Meeting”) of the Company to be held on Wednesday 23 November 2022, starting at 12:00 a.m. (EET) at the Helsinki House of Culture (Finnish: Helsingin Kulttuuritalo), address Sturenkatu 4, Helsinki, Finland. The reception of the shareholders who have registered for the meeting will commence at 10:30 a.m. (EET). No refreshments will be

Nitro Games Oyj: Managers’ Transactions

Person subject to the notification requirementName:                          Nordisk Games A/SPosition:                                   Closely associated person Person Discharging Managerial Responsibilities In IssuerName:                          Mikkel Weider Position:                                  Member of the Board Issuer:                          Nitro Games Oyj LEI:                             743700XPEJZPMWDULF59 Notification type:                      INITIAL NOTIFICATION Reference number:                    19948/6/6 Transaction details

BioStock: Aptahem on the application to initiate clinical studies

Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee in the Netherlands for permission to start a phase I clinical trial with Apta-1. According to the company the study will be initiated on schedule this year. BioStock reached out to the company’s Clinical Research Director, Suzanne Kilany, to learn more about this milestone.Read the full interview with Suzanne Kilany at biostock.se: https://www.biostock.se/en/2022/09/aptahem-on-the-application-to-initiate-clinical-studies/ This is a press release from BioStock - Connecting Innovation &

Update on the Hautalampi Environmental Impact Assessment process

Stockholm, 26 September 2022 – The mining company Eurobattery Minerals AB (Nordic Growth Market: “BAT ” and Börse Stuttgart: “EBM ”; in short: “EBM”, “Eurobattery” or “the Company”), today announces that FinnCobalt Oy, the majority owner of the Hautalampi project, has received a request for additional information for the Hautalampi project Environmental Impact Assessment (EIA) Report from the North Karelia Centre for Economic

Three new board members at Peikko: Liina Jukko, Karen Scrivener, and Teppo Voutilainen

Peikko Group has appointed three new non-executive members to its Board of Directors. The new members were elected by the Extraordinary Annual General Meeting of Peikko Group, and their term will start on the 1st of October 2022. Liina Jukko, M.Sc. Theoretical Physics, is a PhD student in theoretical cosmology at King's College London, in the United Kingdom. She is a third-generation member of the Paananen family, the family that owns Peikko Group Corporation. Karen Scrivener, PhD in Materials Science from Imperial College London, in the United Kingdom, has been Professor and Director

Invitation to Press briefing concerning Ratos AB’s recommended cash offer to the shareholders of Semcon AB

Representatives of the media are welcome to a press briefing at 10.00 a.m. CEST at Ratos's office, Sturegatan 10 in Stockholm.Participants will be Jonas Wiström, President and CEO at Ratos and Markus Granlund, President and CEO at Semcon.It is also possible to participate digitally via Teams.The press briefing will be held in Swedish.Mandatory registration, please contact:Josefine Uppling, Vice President Communication, +46 76 114 54 21 or e-mail josefine.uppling@ratos.comAbout RatosRatos is a business group consisting of 15 companies divided into three business areas:

Statement from the Board of Directors of Semcon in response to Ratos’ public takeover bid

Background This statement is made by the Board of Directors of Semcon AB (publ) (“Semcon” or the “Company") pursuant to section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). On 23 August 2022, Etteplan Oyj (“Etteplan”) announced a public cash takeover bid to the shareholders of Semcon to transfer all of their respective shares in Semcon to Etteplan for a cash consideration of SEK 149 per share in Semcon. On the same date, the Board of Directors of Semcon recommended the shareholders of Semcon to accept this offer. Today, 26 September, Ratos AB (“Ratos”)

Ratos AB announces a recommended cash offer at a price of SEK 157 per share to the shareholders of Semcon AB

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SCHWEIZ, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION

Updated financial calendar

Semcon AB (publ) announces today that, due to the public cash offer situation, the company has updated its financial calendar. The interim report for January-September 2022 will be published on 30 November 2022 at 08.00 a.m.The previously communicated date was 26 October 2022 at 08.00 a.m. The interim report will be published as a press release and available on Semcon’s website: https://semcon.com/investor-relations/reports-presentations/.  New financial calendar 2022/2023 · Interim report January-September 2022: 30 November 2022, 08.00 · Year-end report 2022: 8 February 2023, 08.

There are no items matching the current filter
There are no more items matching the current filter
Back to top